Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2010. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific executive compensation transaction and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only disclosed event is the vesting of shares for a specific director.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction involving Mr. E Gray, who received a payment of £12.69 per ordinary share on December 18, 2010, following the vesting of 11,321.003 ordinary shares under the GlaxoSmithKline Deferred Investment Award.
Investor Verification Points
- Verify the total value of the transaction for Mr. E Gray (11,321.003 shares at £12.69 per share).
- Confirm the date of the transaction (December 18, 2010) and the notification date (December 20, 2010).
- Review the company's annual Form 20-F for comprehensive financial performance data, as this 6-K does not include it.